Tumor-specific AAV delivery of interleukin-12 enhances antitumor immunity and safety in ovarian cancer xenograft mouse model
Molecular Therapy Oncology · 2025-06 · 33 (2) · 201002
DOI: 10.1016/j.omton.2025.201002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2025-06. Verfasst von Chuyuan Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene Therapy, Cure Genetics Co., LTD, Suzhou, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Interleukin-12 (IL-12) is a promising pro-inflammatory cytokine for cancer immunotherapy, but its toxicity and short half-life in serum limit its clinical application. Tumor-targeted delivery of IL-12 by fusion with either antibody or secretion by chimeric antigen receptor T (CAR-T) cells showed reduced systematic toxicity; however, the poor tumor microenvironment (TME) response or the lack of systematic IL-12 regulation still remains risk of low efficacy or high toxicity. Here, we developed TME-specific delivery of IL-12 by a tumor-targeted adeno-associated virus 9 (tAAV9). The tAAV9 was formed by an anti-folate receptor 1 (anti-FOLR1) antibody fragment conjugated with AAV9 via highly efficient Spy-ligation. With targeted infection of FOLR1+ cells in vivo, intravenous (i.v.) administration of tAAV9 specifically delivered IL-12 (tAAV9-IL-12) to TME and significantly suppressed tumor progression with favorable safety profile compared with rAAV9 (recombinant wild-type AAV9) delivery. Moreover, the IL-12 level in the serum was decreased significantly with the suppression of tAAV9-IL-12-infected tumor cell, so that generates promising negative feedback to ensure the safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gene Therapy, Cure Genetics Co., LTD, Suzhou, China.
- Division of Research & Development, Department of Cell Therapy, Cure Genetics Co., LTD, Suzhou, China.
Zitieren
APA
Chen, C., Jiang, Y., Feng, C., Zhou, Q., Luo, X., Cai, L., & Zhao, L. (2025). Tumor-specific AAV delivery of interleukin-12 enhances antitumor immunity and safety in ovarian cancer xenograft mouse model. Molecular Therapy Oncology, 33(2), 201002. https://doi.org/10.1016/j.omton.2025.201002
Vancouver
Chen C, Jiang Y, Feng C, Zhou Q, Luo X, Cai L, et al. Tumor-specific AAV delivery of interleukin-12 enhances antitumor immunity and safety in ovarian cancer xenograft mouse model. Molecular Therapy Oncology. 2025;33(2):201002. doi:10.1016/j.omton.2025.201002
BibTeX
@article{Chen2025,
author = {Chen, Chuyuan and Jiang, Yongji and Feng, Chuan and Zhou, Qingyun and Luo, Xingrong and Cai, Lili and Zhao, Lei},
title = {Tumor-specific AAV delivery of interleukin-12 enhances antitumor immunity and safety in ovarian cancer xenograft mouse model},
journal = {Molecular Therapy Oncology},
year = {2025},
volume = {33},
number = {2},
pages = {201002},
doi = {10.1016/j.omton.2025.201002}
}
EUVIMED